Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated tau. The final product is generated by affinity chromatography using a tau-derived peptide that is phosphorylated at serine 404.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. PubMed: 19546173
Use at an assay dependent concentration.
Use at an assay dependent concentration. PubMed: 22919071
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 45 kDa (predicted molecular weight: 46 kDa).
Transcriptional activator that binds to the consensus sequence 5'-AGATAG-3' and plays a key role in cardiac development (PubMed:24000169). Involved in bone morphogenetic protein (BMP)-mediated induction of cardiac-specific gene expression (By similarity). Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions (By similarity). Acts as a transcriptional activator of ANF in cooperation with NKX2-5 (By similarity). Promotes cardiac myocyte enlargement (PubMed:20081228). Required during testicular development (PubMed:21220346). May play a role in sphingolipid signaling by regulating the expression of sphingosine-1-phosphate degrading enzyme, spingosine-1-phosphate lyase (PubMed:15734735).
Involvement in disease
Atrial septal defect 2 Ventricular septal defect 1 Tetralogy of Fallot Atrioventricular septal defect 4 Testicular anomalies with or without congenital heart disease GATA4 mutations can predispose to dilated cardiomyopathy (CMD), a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
Contains 2 GATA-type zinc fingers.
Methylation at Lys-300 attenuates transcriptional activity.
Western blot - GATA4 (phospho S105) antibody (ab5245)
Predicted band size : 46 kDa
Extracts prepared from cardiomyocytes overexpressing wild-type GATA-4 (1-4 from left to right) stimulated with phenylephrine (PE) for 24 hours were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4°C, then were incubated with 0.35 µg/mL ab5245 for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1), the non-phosphopeptide corresponding to the immunogen (2), a generic phosphoserine-containing peptide (3), or, the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to GATA-4 [pS105] blocks the antibody signal, and that the S105A mutant does not react, thereby demonstrating the specificity of the antibody.
Tae HJ et al. G protein, phosphorylated-GATA4 and VEGF expression in the hearts of transgenic mice overexpressing ß1- and ß2-adrenergic receptors. Mol Med Rep15:4049-4054 (2017).
Read more (PubMed: 28487987) »